Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2004 Jan;90(1):e2.
doi: 10.1136/heart.90.1.e2.

Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost

M Emmel  1 , B Keuth, S Schickendantz
Affiliations
Case Reports

Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost

M Emmel et al. Heart. 2004 Jan.

Abstract

The case of a 14 month old girl with primary pulmonary hypertension treated with domiciliary oxygen is described. After invasive evaluation and testing of nitric oxide with very good response, the testing was repeated to study the effect of inhaled iloprost on pulmonary vascular resistance (PVR). An unexpected and severe increase of PVR was observed, rising from 392 dynes x s x cm(-5) with oxygen to a maximum of 1192 dynes x s x cm(-5) with oxygen and iloprost. Underlying ventilatory and technical problems were excluded. While inhaled iloprost has been described to be highly effective in the treatment of primary pulmonary hypertension, the possibility of contrary "paradoxical" reactions in isolated patients is emphasised, with a dramatic increase of PVR and a possible adverse outcome.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sandoval J, Bauerie O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995;25:466–74. - PubMed
    1. Simon J, Gibbs R. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86 (suppl I):i1–13. - PMC - PubMed
    1. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs 2001;61:1945–56. - PubMed
    1. Wilkins MR, Wharton J. Progress in, and future prospects for, the treatment of primary pulmonary hypertension. Heart 2001;86:603–4. - PMC - PubMed
    1. Rich S, Brundage BH. High dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence of long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135–41. - PubMed

Publication types